Instructions for Nise Aktiv gel (Nimesulide)
Release form
Outdoor gel
Description Nimesulide
Gel for outdoor use from colorless to pale yellow or yellow, transparent, uniform, with a characteristic smell.
1g
nimesulide 10 mg
Auxiliary substances:
dimethyl sulfoxide,
diethylene glycol monoethyl ether,
propylene glycol, citric acid monohydrate,
Sepineo R600 (copolymer acrylamide/acryloyl dimethyl taurate sodium,
isohexadecane, polysorbate 80),
aromatizator "Kalm Valley", water purified.
20 g - tubes made of laminated aluminium (1) with the control of the first opening - cardboard packs.
50 g - tubes made of laminated aluminium (1) with the control of the first opening - cardboard packs.
100 g - tubes made of laminated aluminium (1) with the control of the first opening - cardboard packs.
ATC codes
M01AX17 Nimesulide
Clinical-pharmacological groups / Group affiliation
NSAID for external use
Active substance
nimesulide
Pharmacotherapy group Nimesulide
NSAIDs
Testimony:
- Local symptomatic treatment of inflammatory and degenerative diseases of the musculoskeletal system:
- joint syndrome in acute gout;
- rheumatoid arthritis;
- psoriatic arthritis;
- ankylosing spondyloarthritis;
- osteoarthrosis;
- osteochondrosis with spine syndrome;
- radiculitis;
- inflammatory lesions of ligaments,
- tendons,
- bursitis;
- scias,
- lumbago;
- muscle aches of rheumatic and non-rheumatic origin;
- Post-traumatic inflammation of the soft tissues and the musculoskeletal system (ligament injuries, bruises).
Method of use, course and dosage Nise:
It is applied externally and applied 3-4 times/day to the affected area.
Do not use for more than 10 days without consulting a doctor.
Application in elderly patients
Caution should be exercised in the elderly.
Use in children
It is contraindicated in children under 7 years of age.
It should be used with caution in children older than 7 years.
Nosology (ICD codes)
M05
Seropositive rheumatoid arthritis
M07
Psoriatic and enteropathic arthropathy
M10
Podagra
M15
Polyarthrosis
M19.9
Arthrosis unspecified
M42
Spinal osteochondrosis
M45
Ankylosing spondylitis
M47
Spondylosis
M54.1
Radikulopathy
M54.3
Ishias
M54.4
Lumbago with Sciatica
M65
Synovitis and tenosinovites
M70
Soft tissue diseases related to load, overload and pressure
M71
Other bursopathy
M79.0
Rheumatism unspecified
M79.1
Mialgia
T14.0
Superficial injury of an unspecified area of the body (including abrasion, bruising, bruising, hematoma, bite of a non-venomous insect)
T14.3
Dislocation, stretching and overtension of the capsule-bonding apparatus of the unspecified body region joint
Drugs Nise:
NSAIDs from the class of sulfonanilides, selective competitive reversible COX-2 inhibitor. When applied topically, it has a local analgesic and anti-inflammatory effect.
Reduces the concentration of short-lived prostaglandin H2, a substrate for kinin-stimulated synthesis of prostaglandin E2, in the focus of inflammation and in the ascending pathways of pain impulses in the spinal cord. A decrease in the concentration of prostaglandin E2 (a mediator of inflammation and pain) reduces the activation of prostanoid EP receptors, which is manifested by analgesic and anti-inflammatory effects.
